Leader in Innovative Treatments
for Oxidative Stress

The company’s powerful, targeted therapies aim to stop oxidative tissue damage, a driver of blinding eye diseases and a broad spectrum of serious chronic conditions. Nacuity has several highly differentiated clinical programs, including retinitis pigmentosa, cataract, and cystinosis. Learn more About Us.
The company’s powerful, targeted therapies aim to stop oxidative tissue damage, a driver of blinding eye diseases and a broad spectrum of serious chronic conditions. Nacuity has several highly differentiated clinical programs, including retinitis pigmentosa, cataract, and cystinosis. The company's lead candidate, NPI-001, is being evaluated in the SLO-RP Preserve global, confirmatory Phase 3 clinical trial.

Learn more About Us.

Target_Icon

TARGETED THERAPIES

Developing powerful, targeted, prescription therapies to stop oxidative tissue damage.
FreeRadical_Icon

OXIDATIVE STRESS

Addressing oxidative stress, a driver of blinding eye diseases and a broad spectrum of serious chronic conditions.
Microscope_Icon

CLINICAL PROGRAMS

Advancing first-of-a-kind clinical programs including retinitis pigmentosa, cataract, and cystinosis.
Explore Our Science.